SS Innovations International (NASDAQ: SSII) has reported record second-quarter revenue of $13.9 million, a 39.4% increase year over year, signaling continued momentum for its SSi Mantra surgical robotic platform. The company's first-half revenue reached $25.0 million, up 65.6% from the same period in 2025, driven by a 30.4% rise in system installations to 30 during the quarter. The installed base now stands at 224 SSi Mantra systems across 12 countries, with 12,272 cumulative surgeries performed.
The financial results, announced on August 19, 2026, highlight the company's rapid top-line growth, although gross margin declined to 50.9% from 59.1% in the year-earlier quarter. Gross profit for the quarter increased 20.0% to $7.1 million. For the first half, gross profit rose 77.5% to $12.4 million, with an improved gross margin compared to the prior year.
These figures are particularly significant as SS Innovations prepares for pivotal regulatory milestones. The company is targeting FDA clearance for SSi Mantra by the first quarter of 2027 and EU CE marking by the end of 2026. Achieving these approvals would open access to two of the world's largest healthcare markets, potentially accelerating adoption and revenue growth.
The company's telesurgery achievements are also extending the clinical profile of SSi Mantra. By demonstrating the ability to perform remote surgeries, SS Innovations is not only showcasing the system's technical capabilities but also expanding its potential applications in underserved regions where specialist surgeons are scarce. This could differentiate SSi Mantra in a competitive market dominated by established players like Intuitive Surgical's da Vinci system.
System installations remain the primary commercial growth driver, and the recent uptick suggests sustained demand. The expansion across 12 countries indicates a broadening international footprint, which diversifies revenue streams and reduces dependence on any single market. However, the decline in gross margin warrants attention, as it could reflect increased costs associated with scaling production or competitive pricing pressures.
Investors are likely to view these results as a positive indicator of the company's execution and market traction. The combination of strong revenue growth, a growing installed base, and upcoming regulatory catalysts positions SS Innovations for potential expansion. Still, the company faces challenges, including the need to manage margins and navigate the rigorous regulatory process.
As SS Innovations continues to penetrate the surgical robotics market, its ability to secure regulatory approvals and maintain growth will be critical. The record quarterly revenue and sustained adoption of SSi Mantra provide a solid foundation for the company's future prospects.
